| [1] |
中华医学会呼吸病学分会. 侵袭性肺真菌病诊断与治疗指南(2025年版)[J]. 中华结核和呼吸杂志, 2025, 48(12):1104-1126. doi:10.3760/cma.j.cn112147-20250819-00501.
|
| [2] |
禹小波. 质子泵抑制剂与三唑类抗真菌药物的相互作用研究进展[J]. 临床合理用药, 2025, 18(29):178-180, 封3. doi:10.15887/j.cnki.13-1389/r.2025.29.052.
|
| [3] |
Czyrski A, Resztak M, S'widerski P, et al. The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles[J]. Pharmaceutics, 2021, 13(11):1961. doi:10.3390/pharmaceutics13111961.
|
| [4] |
田丽凤, 王莉, 邱雄泉, 等. 基于FDA不良事件报告系统数据库的奥美拉唑联用伏立康唑不良反应信号比值失衡分析[J]. 临床药物治疗杂志, 2025, 23(1):82-86. doi:10.3969/j.issn.1672-3384.2025.01.015.
|
| [5] |
Jiang Z, Li J, Zhao C, et al. Voriconazole-induced visual abnormality based on drug interaction between voriconazole and esomeprazole:A case report[J]. Int J Clin Pharmacol Ther, 2023, 61(10):460-465. doi:10.5414/CP204321.
|
| [6] |
Cabral B M I, Edding S N, Portocarrero J P, et al. Rhabdomyolysis[J]. Dis Mon, 2020, 66(8):101015. doi:10.1016/j.disamonth.2020.101015.
|
| [7] |
Zutt R, van der Kooi A J, Linthorst G E, et al. Rhabdomyolysis:review of the literature[J]. Neuromuscul Disord, 2014, 24(8):651-659. doi:10.1016/j.nmd.2014.05.005.
|
| [8] |
何珂, 刘玲, 卞荣蓉, 等. 老年患者慢性腹泻致严重低钾血症合并横纹肌溶解症1例[J]. 中国医药导报, 2019, 16(24):166-168.
|
| [9] |
Kodadek L, Carmichael Ii S P, Seshadri A, et al. Rhabdomyo-lysis:an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document[J]. Trauma Surg Acute Care Open, 2022, 7(1):e000836. doi:10.1136/tsaco-2021-000836.
|
| [10] |
吴晓平, 张永良. 盐酸莫西沙星片与伏立康唑片联用致周围神经病变1例分析[J]. 中国药物警戒, 2026, 23(2):210-212. doi:10.19803/j.1672-8629.20250527.
|
| [11] |
Happaerts S, Wieërs M, Vander Mijnsbrugge W, et al. Azole-Induced Myositis after Combined Lung-Liver Transplantation[J]. Case Rep Transplant, 2022, 2022:7323755. doi:10.1155/2022/7323755.
|
| [12] |
刘晓月, 马洁, 曹译丹, 等. 伏立康唑致肌酸激酶升高一例[J]. 临床药物治疗杂志, 2021, 19(6):90-92. doi:10.3969/j.issn.1672-3384.2021.06.013.
|
| [13] |
肖桂荣, 徐珽. 伏立康唑致肌病1例[J]. 四川医学, 2017, 38(4):481-482. doi:10.16252/j.cnki.issn1004-0501-2017.04.034.
|
| [14] |
Soliman M, Akanbi O, Harding C, et al. Voriconazole-induced Myositis in a Double Lung Transplant Recipient[J]. Cureus, 2019, 11(2):e3998. doi:10.7759/cureus.3998.
|
| [15] |
Naranjo C A, Busto U, Sellers E M, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2):239-245. doi:10.1038/clpt.1981.154.
|
| [16] |
罗梦林, 蔡小利, 叶飞. 利用艾司奥美拉唑调整伏立康唑血药浓度治疗曲霉菌感染的案例分析[J]. 药物流行病学杂志, 2021, 30(6):408-410.
|
| [17] |
黄清茹, 丁水莲, 陈婷婷. 肺部真菌感染患者中质子泵抑制剂与伏立康唑的药物相互作用[J]. 海峡药学, 2025, 37(2):68-72. doi:10.3969/j.issn.1006-3765.2025.02.018.
|
| [18] |
Jing S, Zhang X, Zhang Y, et al. Pharmacovigilance analysis of myopathy associated with azoles and nonstatins interactions based on US FAERS database[J]. Sci Rep, 2025, 15(1):39870. doi:10.1038/s41598-025-23424-x.
|
| [19] |
曲彩红, 雷姿颖. 伏立康唑与埃索美拉唑联用致乙肝肝硬化并肺部侵袭性真菌感染患者横纹肌溶解症[J]. 今日药学, 2011, 21(11):686-688.
|
| [20] |
曾芝雨, 李东良. 伏立康唑与埃索美拉唑相互作用致肝衰竭患者横纹肌溶解一例[J]. 中华传染病杂志, 2018, 36(2):116-117. doi:10.3760/cma.j.issn.1000-6680.2018.02.014.
|
| [21] |
Huo B N, Shu L, Xiao J W, et al. Clinical drug interactions between voriconazole and 38 other drugs:a retrospective analysis of adverse events[J]. Front Pharmacol, 2024, 15:1292163. doi:10.3389/fphar.2024.1292163.
|
| [22] |
Mafuru M, Wu S, Mayala H, et al. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole[J]. Pharmgenomics Pers Med, 2021, 14:1379-1389. doi:10.2147/PGPM.S329662.
|
| [23] |
Tian Y, Jin M, Ning H. A post-marketing pharmacovigilance study of triazole antifungals:adverse event data mining and analysis based on the FDA adverse event reporting system database[J]. Front Pharmacol, 2025, 16:1462510. doi:10.3389/fphar.2025.1462510.
|
2026, Vol. 7 
京公安网备11010202008787号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
